Marker for evaluating immune state of COVID-19 vaccine and application thereof

The invention discloses a marker for evaluating the immune state of a COVID-19 vaccine and application of the marker. The marker comprises any one or a combination of at least two of an M1 peptide, an N16 peptide, an N24 peptide, an S15 peptide, an S39 peptide, an S44 peptide, an S64 peptide, an S82...

Full description

Saved in:
Bibliographic Details
Main Authors ZHENG PEIYAN, CHENG ZHANGKAI, HUANG HUIMIN, XUE MINGSHAN, SUN BAOQING, LUO WENTING
Format Patent
LanguageChinese
English
Published 25.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention discloses a marker for evaluating the immune state of a COVID-19 vaccine and application of the marker. The marker comprises any one or a combination of at least two of an M1 peptide, an N16 peptide, an N24 peptide, an S15 peptide, an S39 peptide, an S44 peptide, an S64 peptide, an S82 peptide, an S95 peptide, an S104 peptide or an S115 peptide of the SARS-CoV-2 virus. According to the method, the difference of peptide specific antibody responses between an asymptomatic patient and a symptomatic patient is accurately identified, the difference of responses to peptides such as M1, N24, S15, S64, S82, S104 and S115 between a vaccinated person and an infected person is determined through a clustering heat map, the infected patient and an vaccinated person can be effectively distinguished, the asymptomatic patient and the symptomatic patient can be effectively distinguished, and the method is suitable for clinical application. And reference is provided for development of COVID-19 treatment and pepti
Bibliography:Application Number: CN202310046908